小程序掃碼下單
本網站銷售的所有產品僅用于工業應用或者科學研究等非醫療目的，不可用于人類或動物的臨床診斷或者治療，非藥用，非食用。
Abatacept
英文名：Unii-7D0yb67S97
Cas號：332348-12-6
Cas號：332348-12-6
檢測信息查詢
| 貨號 | 規格 | 貨期 | 庫存 | 價格 | 促銷價 | 訂購 |
| 13081324961-1mg | 99.00% | 0 | ￥11000 | |||
| 13081324961-5mg | 99.00% | 0 | ￥19600 |
| 別 名 | Unii-7D0yb67S97 |
| Cas號 | 332348-12-6 |
| M D L | |
| 分子式 | |
| 分子量 | |
| 產品參數 | Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Description Abatacept (CTLA4lg) is a soluble fusion protein consisting of the extra-cellular domain of human CTLA4 and a fragment of the Fc portion of human IgG1 (hinge and CH2 and 3 domains)[1]. Abatacept is a selective T-cell co-stimulation modulator and a protein drug for the autoimmune diseases[2]. |
| 性狀 | Abatacept (CTLA4lg) 是一種可溶性融合蛋白，由人 CTLA4 的胞外結構域和人 IgG1 Fc 部分的片段 (鉸鏈，CH2 和 3 結構域) 組成。Abatacept 是選擇性 T 細胞共刺激調節劑，也是一種用于自身免疫性疾病的蛋白藥物。 |
| 貯存 | Storage Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month References [1]. Kiykim A, et al. Abatacept as a Long-Term Targeted Therapy for LRBA Deficiency. J Allergy Clin Immunol Pract. 2019 Jun 22. [2]. Lon HK, et al. Modeling pharmacokinetics/pharmacodynamics of abatacept and disease progression in collagen-induced arthritic rats: a population approach. J Pharmacokinet Pharmacodyn. 2013 Dec;40(6):701-12. [3]. Patakas A, et al. Abatacept Inhibition of T Cell Priming in Mice by Induction of a Unique Transcriptional Profile That Reduces Their Ability to Activate Antigen-Presenting Cells. Arthritis Rheumatol. 2016 Mar;68(3):627-38. |
- 維多珠單抗 943609-66-3
- 優特克諾 815610-63-0
- 雷莫蘆單抗 947687-13-0
- Human IgG1 Control
- Abatacept 332348-12-6
- Obinutuzumab
- Reslizumab 241473-69-8
- 那他珠單抗 189261-10-7
- BENRALIZUMAB 1044511-01-4
滬公網安備 31012002003054號